Clinical Trial Update: Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection [Phase 3]

View source ↗

Summary

Completed Phase 3 open-label study comparing dolutegravir and efavirenz for HIV/TB co-infection; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection
• Tuberculosis

Drugs mentioned

• Dolutegravir (dolutegravir)
• EFAVIRENZ (efavirenz)

Snippet

Sponsor: ViiV Healthcare | Conditions: Infection, Human Immunodeficiency Virus, HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2019-02-21